Citation Impact
Citing Papers
Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008
2008 Standout
Medicine & science in sports & exercise
1994 Standout
KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins
2014
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
2023 StandoutNobel
Role of nitric oxide in inflammatory diseases
2007 Standout
Regulation of hepatic stellate cells by connective tissue growth factor
2012
ROCK induced inflammation of the microcirculation during endotoxemia mediated by nitric oxide synthase
2011
Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin
2020 StandoutNobel
Changes of Intestinal Functions in Liver Cirrhosis
2016 Standout
Adverse Health Effects of Marijuana Use
2014 Standout
The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
2008
Mechanisms of hepatic stellate cell activation
2017 Standout
Effects of Type II diabetes on muscle microvascular oxygen pressures
2006
Diagnosis and treatment of acute renal failure in patients with cirrhosis
2007
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
2006
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
2013
Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects
2011 Standout
Dysbalance in sympathetic neurotransmitter release and action in cirrhotic rats: Impact of exogenous neuropeptide Y
2012
Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial
2009
Role of Differentiation of Liver Sinusoidal Endothelial Cells in Progression and Regression of Hepatic Fibrosis in Rats
2011
Vascular disorders of the liver # †
2008 Standout
Endocannabinoids in liver disease
2010
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
2016 Standout
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia
2004
Acute renal failure in patients with cirrhosis: Perspectives in the age of MELD
2003
The role of nitric oxide
2006
The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat
2004
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis
2007
Portal hypertensive bleeding in cirrhosis
2016 Standout
cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
2010 Standout
Sepsis and septic shock
2018 Standout
Mechanisms of Hepatic Fibrogenesis
2008 Standout
Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation
2008
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
2018 Standout
Management of Varices and Variceal Hemorrhage in Cirrhosis
2010
Rapamycin: Something Old, Something New, Sometimes Borrowed and Now Renewed
2007
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
TGF-β and fibrosis in different organs — molecular pathway imprints
2009 Standout
The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension
2006
Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis
2013 Standout
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
2009
Vascular mediators in the injured liver
2003
Natural compounds for cancer treatment and prevention
2009 Standout
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
2011 Standout
Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony
2019 Standout
Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats
2012
Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term
2005
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
2007
Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1α through mTOR-dependent pathway
2014
Cellular senescence: from physiology to pathology
2014 Standout
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Lanthanum Chloride Inhibits LPS Mediated Expressions of Pro-Inflammatory Cytokines and Adhesion Molecules in HUVECs: Involvement of NF-κB-Jmjd3 Signaling
2017 Standout
Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis
2021
Cannabinoids as Novel Anti-Inflammatory Drugs
2009
Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis
2021
Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung
2015
Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells
2011
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
2018 Standout
The Vascular Endothelium and Human Diseases
2013 Standout
Works of Erwin Biecker being referenced
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension
2001
Benign Hepatic Tumours
2003
Vascular dysfunction in human and rat cirrhosis: Role of receptor-desensitizing and calcium-sensitizing proteins
2007
Portal hypertension is associated with increased mRNA levels of vasopressor G‐protein‐coupled receptors in human hepatic arteries
2003
Long-Term Treatment of Bile Duct-Ligated Rats with Rapamycin (Sirolimus) Significantly Attenuates Liver Fibrosis: Analysis of the Underlying Mechanisms
2005
Evidence for the involvement of endothelin-1 but not urotensin-II in chronic lower limb ischaemia in man
2003
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase
2007
Nitric oxide synthase 1 is partly compensating for nitric oxide synthase 3 deficiency in nitric oxide synthase 3 knock‐out mice and is elevated in murine and human cirrhosis
2004
Vasodilator mRNA levels are increased in the livers of portal hypertensive NO‐synthase 3‐deficient mice
2004
Defective RhoA/Rho-Kinase Signaling Contributes to Vascular Hypocontractility and Vasodilation in Cirrhotic Rats
2006
Potential role of endothelin 1 in ischaemia-induced angiogenesis in critical leg ischaemia
2002
Endothelin A-receptor blockade in experimental diabetes improves glucose balance and gastrointestinal function
2002